Cascades Analytics is a research and advisory platform dedicated to understanding the science, strategy, and development of psychedelic and neuroplastogen therapeutics.
Founder
Alexandre Stipanovich, PhD, Founder and Editor
Alexandre is a neuropsychopharmacology researcher and industry analyst based in New York, who founded Cascades Analytics in 2024. He completed his PhD at Pierre and Marie Curie University Paris VI, where his thesis work was published in Nature. He subsequently conducted postdoctoral research at Yale School of Medicine in the laboratory of Angus Nairn, and at Rockefeller University in the laboratory of Nobel Laureate Paul Greengard, studying signaling pathways involved in neuroplasticity and psychiatric drug action.
Over the past several years, Alexandre has focused on the emerging field of psychedelic and neuroplastogen therapeutics, where advances in receptor pharmacology, neural plasticity, and drug design are opening new approaches to treating mental health disorders.
Through Cascades Analytics, he bridges academic neuroscience, biotech development, and investment decision-making, providing clear analysis of how compounds move from receptor pharmacology to clinical trials and ultimately to patients.
Contributors
Tanya Ramey, MD, PhD, Clinical Scientific Contributor
Tanya is a physician-scientist with over 20 years in CNS drug development. At Eli Lilly and then Pfizer, she led clinical development on duloxetine, pregabalin, ziprasidone, and varenicline. She then spent a decade as a program director at NIDA (the National Institute on Drug Abuse), where she authored the institute’s funding call for psychedelic research in substance use disorders. Most recently, she was Chief Medical Officer at Usona Institute, overseeing its psilocybin program in major depressive disorder through Phase III. She is a founding member of ISCTM (the International Society for CNS Clinical Trials and Methodology) and runs her own advisory firm, Altair. For Cascades Analytics, she covers the problems in psychedelic trial design and how to fix them.
Odette Alina Hauke, Regulatory Science and Policy Contributor
Odette is an epidemiologist and regulatory scientist with more than 13 years of experience in complex therapeutics, ibogaine development, and global regulatory strategy, including roles at Regeneron and AtaiBeckley. She presented at the FDA’s public hearing on psychedelics in September 2026, and earlier that year spoke on the regulatory and safety profile of ibogaine at ISRP (the International Society for Research on Psychedelics). For Cascades Analytics, she covers the paths to approval, reimbursement, rescheduling, and patient access.
Founder
Alexandre Stipanovich, PhD, Founder and Editor
Alexandre is a neuropsychopharmacology researcher and industry analyst based in New York, who founded Cascades Analytics in 2024. He completed his PhD at Pierre and Marie Curie University Paris VI, where his thesis work was published in Nature. He subsequently conducted postdoctoral research at Yale School of Medicine in the laboratory of Angus Nairn, and at Rockefeller University in the laboratory of Nobel Laureate Paul Greengard, studying signaling pathways involved in neuroplasticity and psychiatric drug action.
Over the past several years, Alexandre has focused on the emerging field of psychedelic and neuroplastogen therapeutics, where advances in receptor pharmacology, neural plasticity, and drug design are opening new approaches to treating mental health disorders.
Through Cascades Analytics, he bridges academic neuroscience, biotech development, and investment decision-making, providing clear analysis of how compounds move from receptor pharmacology to clinical trials and ultimately to patients.
Contributors
Tanya Ramey, MD, PhD, Clinical Scientific Contributor
Tanya is a physician-scientist with over 20 years in CNS drug development. At Eli Lilly and then Pfizer, she led clinical development on duloxetine, pregabalin, ziprasidone, and varenicline. She then spent a decade as a program director at NIDA (the National Institute on Drug Abuse), where she authored the institute’s funding call for psychedelic research in substance use disorders. Most recently, she was Chief Medical Officer at Usona Institute, overseeing its psilocybin program in major depressive disorder through Phase III. She is a founding member of ISCTM (the International Society for CNS Clinical Trials and Methodology) and runs her own advisory firm, Altair. For Cascades Analytics, she covers the problems in psychedelic trial design and how to fix them.
Odette Alina Hauke, Regulatory Science and Policy Contributor
Odette is an epidemiologist and regulatory scientist with more than 13 years of experience in complex therapeutics, ibogaine development, and global regulatory strategy, including roles at Regeneron and AtaiBeckley. She presented at the FDA’s public hearing on psychedelics in September 2026, and earlier that year spoke on the regulatory and safety profile of ibogaine at ISRP (the International Society for Research on Psychedelics). For Cascades Analytics, she covers the paths to approval, reimbursement, rescheduling, and patient access.